Start adding items to your reading lists:
Save this item to:
This item has been saved to your reading list.

A range of publications and thought leadership is available to UK pharmaceuticals companies:

Implications of the EU Referendum

What are the relevant issues to the Pharma and Life Sciences Industries following the EU Referendum?

From vision to decision: Pharma 2020

Predicting pharma’s future trends and the decisions companies need to make to capitalise on the opportunities

Pharma M&A; Deals quarter two 2012

Overview of Pharmaceutical mergers and acquisitions activity 2012, Quarter two.

Pharmaceutical sector shows steady deal flow

With our latest analysis ofPharmaceutical (Pharma) merger and acquisition (M&A;) deals our specialists, Michelle Ritchie, Steve Aherne, Lucy Stapleton, Andrew McKechnie and Jo Pisani talk about what current trends and future opportunities we are seeing in the market.Our analysis is based on the deal tracking done by Dealogic and we have found that Pharma is not immune to the economic downturn, and this has clearly impacted the number of deals that have happened this year.

Prescription suggests improving outlook

Our latest pharma M&A; insights look at pharma deal activity over 2011 and Q1 2012.

Pharma 2020: Supplying the future

Pharma companies need to revisit their supply chains to be able to respond to the industry’s future needs.

Pharma 2020: Role of the supply chain

Listen to Johnathon Marshall, Pharma & Life Sciences Advisory Director, to get our perspectives on the role of the supply chain in the future of the pharmaceuticals industry.

Pharma 2020: Virtual R&D; - Which path will you take?

The second paper in the PwC Pharma 2020 series explores how pharma companies could dramatically improve the R&D; productivity

Pharma 2020: Taxing times ahead - Which path will you take?

Pharma 2020: Taxing times - Which path will you take?

Contact us

Andrew Packman
Total Tax Contribution and Tax Transparency leader
Tel: +44 (0)189 552 2104

Follow us